iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
Clinical trial NCT02802943 · COMPLETED
Trial details
- NCT number
- NCT02802943
- Sponsor
- University Hospital Tuebingen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-05
- Primary completion
- 2022-09-30
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.